‘Our Commitment Is Serious’: Fresenius Kabi’s CEO Pierluigi Antonelli On Biosimilars And Beyond
Fresenius Kabi is drawing closer to the conclusion of its Vision 2026 strategic roadmap. The company’s CEO, Pierluigi Antonelli, talks to Generics Bulletin about the company’s results so far and how it’s investments in biosimilars, acquisitions and manufacturing is paying off.